David C Swinney

Summary

Publications

  1. doi request reprint How were new medicines discovered?
    David C Swinney
    Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Nat Rev Drug Discov 10:507-19. 2011
  2. doi request reprint Phenotypic vs. target-based drug discovery for first-in-class medicines
    D C Swinney
    Institute for Rare and Neglected Diseases Drug Discovery, Mountain View, California, USA
    Clin Pharmacol Ther 93:299-301. 2013
  3. doi request reprint Steady-state kinetic characterization of kinase activity and requirements for Mg2+ of interleukin-1 receptor-associated kinase-4
    Mohammad Hekmat-Nejad
    Department of Virology, Roche Palo Alto, LLC, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Biochemistry 49:1495-506. 2010
  4. doi request reprint 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead
    Michael Soth
    Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA
    Bioorg Med Chem Lett 21:3452-6. 2011
  5. doi request reprint Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate
    Derek R Latour
    Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, CA, United States
    Antiviral Res 87:213-22. 2010
  6. pmc Characterization of the elongation complex of dengue virus RNA polymerase: assembly, kinetics of nucleotide incorporation, and fidelity
    Zhinan Jin
    Virology DTA, Roche Palo Alto LLC, Palo Alto, California 94034, USA
    J Biol Chem 286:2067-77. 2011
  7. ncbi request reprint Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay
    Eva Papp
    Department of Biochemical Pharmacology, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Biochemistry 46:15103-14. 2007
  8. ncbi request reprint The role of binding kinetics in therapeutically useful drug action
    David C Swinney
    Roche Palo Alto, CA 94304, USA
    Curr Opin Drug Discov Devel 12:31-9. 2009
  9. ncbi request reprint Kinetic characterization of human JNK2alpha2 reaction mechanism using substrate competitive inhibitors
    Linghao Niu
    Department of Biochemical Pharmacology, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Biochemistry 46:4775-84. 2007
  10. ncbi request reprint Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety
    David C Swinney
    Biochemical Pharmacology, Roche Palo Alto, 3431 Hillview Ave Palo Alto, CA 94304, USA
    Curr Top Med Chem 6:461-78. 2006

Collaborators

  • Jerome Deval
  • Zhinan Jin
  • Gabrielle Heilek
  • J Michael Bradshaw
  • Andreas Jekle
  • Ronald J Hill
  • Mohammad Hekmat-Nejad
  • David M Goldstein
  • Eva Papp
  • Michael Soth
  • Derek R Latour
  • Patricia Tran
  • David Shaw
  • Linghao Niu
  • Kieran Durkin
  • Rebecca Suttman
  • Andreas Kuglstatter
  • Joel Mcintosh
  • Roland Billedeau
  • Sarah Abbot
  • Brian Wong
  • Hasim Zecic
  • Fujun Li
  • Manjiri Ghate
  • Man Ling Sung
  • Paul Weller
  • Martin Stahl
  • Nidhi Arora
  • Kristen McCaleb
  • Tobias Gabriel
  • Jaehyeon Park
  • Allassan Abubakari
  • Brad Loe
  • Nolan Dewdney
  • Humberto Arzeno
  • Sandra Frauchiger
  • Robert Henningsen
  • Hassan Javanbakht
  • Stephen J Lok
  • Ina Lee
  • Jim Li
  • Peter Gee
  • Klaus Klumpp
  • Seth F Harris
  • Sandra M Wang
  • Suping Ren
  • Alan K Kutach
  • Fengrong Zuo
  • Stacy Wilson
  • Hoangdung Ho
  • Jim Barnett
  • Joyce K Y Tse
  • Simon Lee
  • Sandra Wang
  • Kung Ching Chang

Detail Information

Publications10

  1. doi request reprint How were new medicines discovered?
    David C Swinney
    Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Nat Rev Drug Discov 10:507-19. 2011
    ..We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development...
  2. doi request reprint Phenotypic vs. target-based drug discovery for first-in-class medicines
    D C Swinney
    Institute for Rare and Neglected Diseases Drug Discovery, Mountain View, California, USA
    Clin Pharmacol Ther 93:299-301. 2013
    ..The rationalization for this success was the unbiased identification of the molecular mechanism of action (MMOA)...
  3. doi request reprint Steady-state kinetic characterization of kinase activity and requirements for Mg2+ of interleukin-1 receptor-associated kinase-4
    Mohammad Hekmat-Nejad
    Department of Virology, Roche Palo Alto, LLC, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Biochemistry 49:1495-506. 2010
    ....
  4. doi request reprint 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead
    Michael Soth
    Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA
    Bioorg Med Chem Lett 21:3452-6. 2011
    ..Learnings from previous Roche p38-selective inhibitors were applied to a new fragment hit, which was optimized to a potent, exquisitely selective preclinical lead with a good pharmacokinetic profile...
  5. doi request reprint Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate
    Derek R Latour
    Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, CA, United States
    Antiviral Res 87:213-22. 2010
    ..Overall, beta-d-2'-ethynyl-7-deaza-adenosine provides a promising scaffold for the development of inhibitors of dengue virus polymerase...
  6. pmc Characterization of the elongation complex of dengue virus RNA polymerase: assembly, kinetics of nucleotide incorporation, and fidelity
    Zhinan Jin
    Virology DTA, Roche Palo Alto LLC, Palo Alto, California 94034, USA
    J Biol Chem 286:2067-77. 2011
    ..This work reports the first description of presteady-state kinetics and fidelity for an RNA-dependent RNA polymerase from the Flaviviridae family...
  7. ncbi request reprint Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay
    Eva Papp
    Department of Biochemical Pharmacology, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Biochemistry 46:15103-14. 2007
    ..The findings presented here provide the first kinetic description of the Syk enzyme mechanism...
  8. ncbi request reprint The role of binding kinetics in therapeutically useful drug action
    David C Swinney
    Roche Palo Alto, CA 94304, USA
    Curr Opin Drug Discov Devel 12:31-9. 2009
    ..The value of binding kinetics to drug discovery will be increased through an improved ability to identify optimal kinetic mechanisms and define kinetic structure activity relationships...
  9. ncbi request reprint Kinetic characterization of human JNK2alpha2 reaction mechanism using substrate competitive inhibitors
    Linghao Niu
    Department of Biochemical Pharmacology, Roche Palo Alto LLC, 3431 Hillview Avenue, Palo Alto, California 94304, USA
    Biochemistry 46:4775-84. 2007
    ....
  10. ncbi request reprint Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety
    David C Swinney
    Biochemical Pharmacology, Roche Palo Alto, 3431 Hillview Ave Palo Alto, CA 94304, USA
    Curr Top Med Chem 6:461-78. 2006
    ..This principle appears to be independent of target class and provides insight as to intrinsic biochemical features and approaches required for a maximal therapeutic index...